Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind randomized comparison of ridinilazole versus vancomycin for Clostridioides difficile infection
MOH_2018-07-16_002489Phase 3Completed
- Sponsor
- Summit Therapeutics
- Start
- Jun 2018
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Clostridioides difficile colitis (CDI) comparing Ridinilazole arm with Vancomycin arm (2 arms). Started Jun 2018; status: completed.
02
Drugs
ridinilazolevancomycin
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on MOH_2018-07-16_002489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-07-16_002489.